NF-κB activating scaffold proteins as signaling molecules and putative therapeutic targets

被引:13
作者
Chariot, A
Meuwis, MA
Bonif, M
Leonardi, A
Merville, MP
Gielen, J
Piette, J
Siebenlist, U
Bours, V
机构
[1] CHU Sart Tilman, Lab Med Chem & Human Genet, B-4000 Liege, Belgium
[2] CHU Sart Tilman, Ctr Cellular & Mol Therapy, Lab Virol & Immunol, B-4000 Liege, Belgium
[3] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Naples, Italy
[4] CNR, Ist Endocrinol & Oncol Sperimentale, I-00185 Rome, Italy
[5] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA
关键词
NF-kappa B; scaffold proteins; IKK; NEMO/IKK gamma; genetic diseases; cancer; inflammation; X-LINKED DISORDER; TNF RECEPTOR; GENE-EXPRESSION; ECTODERMAL DYSPLASIA; MISSENSE MUTATIONS; BINDING-PROTEIN; ADAPTER PROTEIN; IKK ACTIVATION; KINASE; INTERLEUKIN-1;
D O I
10.2174/0929867033457926
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Activation of transcription factors such as NF-kappaB occurs through signaling pathways involving sequential phosphorylation of a variety of substrates by distinct kinases. Proper assemby and activation of these kinases require interaction with non-enzymatic and essential partners named scaffold proteins. Here, we describe how the NF-kappaB activating scaffold proteins involved in the signaling pathways triggered by the proinflammatory cytokines TNFalpha, IL-1beta and by the CD40 ligand play such roles. We also illustrate the human genetic diseases that are linked to mutations affecting genes coding for these proteins. We suggest that these scaffold proteins may be specifically targeted by novel therapeutical agents for the treatment of inflammation or cancers.
引用
收藏
页码:593 / 602
页数:10
相关论文
共 85 条
[1]   The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells [J].
Ahonen, CL ;
Manning, EM ;
Erickson, LD ;
O'Connor, BP ;
Lind, EF ;
Pullen, SS ;
Kehry, MR ;
Noelle, RJ .
NATURE IMMUNOLOGY, 2002, 3 (05) :451-456
[2]   NF-κB signaling and human disease [J].
Aradhya, S ;
Nelson, DL .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2001, 11 (03) :300-306
[3]   Regulation of the subcellular localization of tumor necrosis factor receptor-associated factor (TRAF)2 by TRAF1 reveals mechanisms of TRAF2 signaling [J].
Arron, JR ;
Pewzner-Jung, Y ;
Walsh, MC ;
Kobayashi, T ;
Choi, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (07) :923-934
[4]   Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain [J].
Baud, V ;
Liu, ZG ;
Bennett, B ;
Suzuki, N ;
Xia, Y ;
Karin, M .
GENES & DEVELOPMENT, 1999, 13 (10) :1297-1308
[5]  
BEBERICH I, 1994, J IMMUNOL, V153, P4357
[6]   Regulatory functions of ubiquitination in the immune system [J].
Ben-Neriah, Y .
NATURE IMMUNOLOGY, 2002, 3 (01) :20-26
[7]   Regulation of TRAF2 signaling by self-induced degradation [J].
Brown, KD ;
Hostager, BS ;
Bishop, GA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (22) :19433-19438
[8]   MyD88, an adapter protein involved in interleukin-1 signaling [J].
Burns, K ;
Martinon, F ;
Esslinger, C ;
Pahl, H ;
Schneider, P ;
Bodmer, JL ;
Di Marco, F ;
French, L ;
Tschopp, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (20) :12203-12209
[9]   Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor [J].
Burns, K ;
Clatworthy, J ;
Martin, L ;
Martinon, F ;
Plumpton, C ;
Maschera, B ;
Lewis, A ;
Ray, K ;
Tschopp, J ;
Volpe, F .
NATURE CELL BIOLOGY, 2000, 2 (06) :346-351
[10]   IRAK: A kinase associated with the interleukin-1 receptor [J].
Cao, ZD ;
Henzel, WJ ;
Gao, XO .
SCIENCE, 1996, 271 (5252) :1128-1131